A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

INDIANAPOLIS — Hoosiers with diabetes call it a game-changer. The announcement Wednesday from Eli Lilly, that the drugmaker would cap out-of-pocket insulin costs is welcome news, especially after ...

INDIANAPOLIS, Ind. — Eli Lilly and Co. announced plans for a major nationwide investment to expand operations, including an $85 million commitment in Indianapolis. It’s part of an overall $85… ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Eli Lilly and Co., announced Wednesday that it will reduce the price of insulin and cap the monthly cost to most of its insulin users at $35 starting in May, putting the life saving drug within ...

Eli Lilly and Company will expand its global R&D headquarters in Indianapolis, IN, adding 130,000 square feet to the company's existing complex.

Eli Lilly and Co. on Monday morning announced plans to add a 130,000-square-foot building to its Indianapolis research-and-development headquarters. The $70 million investment is the latest in a ...

Eli Lilly said Nov. 20 it plans to invest $400 million to expand its Lilly Technology Center in Indianapolis and add 100 jobs for technicians, scientists and engineers.